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Abstract. Background/Aim: The aim of this retrospective
cohort study was to investigate the association between renal
dysfunction (RD) and the development of oral mucositis (OM)
in patients undergoing concurrent chemoradiotherapy
(CCRT) for pharyngeal cancer including radiation to the oral
cavity. Patients and Methods: Of 130 patients diagnosed as
having pharyngeal cancer who received CCRT at the
Okayama University Hospital Head and Neck Cancer Center,
44 were finally selected. Results: During the observation
period, 24 (54.5%) patients experienced severe OM 
(grade 3). The Cox proportional hazards regression model
demonstrated that RD (hazard ratio(HR)=2.45, 95%
confidence interval(CI)=1.067-6.116, p=0.035) and
nasopharynx/oropharynx as center of the irradiated area
(HR=2.56, 95% CI=1.072-5.604, p=0.034) were significantly
associated with the incidence of severe OM (grade 3).
Conclusion: In patients with pharyngeal cancer treated with
CCRT including radiation to the oral cavity, RD at baseline
can be a risk factor for developing severe OM.
In Japan in 2009, the number of patients with head and neck
cancer (HNC) was estimated to be about 19,000, and
approximately 3,300 patients died due to HNC (1). In order
to reduce mortality, concurrent chemoradiotherapy (CCRT),
which was found to be superior to radiotherapy with respect
to progression-free survival, has been widely adopted as the
standard non-surgical approach in HNC (2-4). However,
since CCRT for HNC often uses a platinum-based regimen
(5), CCRT induces side-effects including mucositis,
xerostomia, oropharyngeal candidiasis, and neurosensory
disorders (mucosal pain and taste dysfunction) (6). In
particular, oral mucositis (OM) clearly has an adverse impact
on patients’ quality of life because of pain, i.e. difficulty in
eating, swallowing and talking (7,8). Furthermore, severe
OM interrupts the cancer treatment course, induces weight
loss, and increases the treatment cost (9-12). Thus, the
control of OM in cancer treatment is very important.
The risk factors for developing OM during cancer
treatment are not fully understood. Risk factors have been
attributed to both the therapy regimen and patient
characteristics (13). However, even though diagnosis and
treatment may be similar, patients are not at equal risk of
mucositis (14). Patient-related risk factors can be complex,
including systemic conditions.
Among systemic conditions, renal dysfunction (RD) is one
of the basic conditions that should be carefully considered in
patients with cancer, and drug dosage adjustments are often
necessary in CCRT. Although RD affects the metabolism of
anticancer agents (15), the association between RD and OM
development during cancer treatment such as CCRT remains
unclear. Thus, we hypothesized that RD is a risk factor for
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developing OM in CCRT. The aim of this study was to
investigate the association between RD and OM in patients
undergoing CCRT for pharyngeal cancer including radiation
to the oral cavity. Because the area irradiated in patients with
pharyngeal cancer often includes the oral cavity, the
inclusion criteria of this study were pharyngeal cancer and
treatment with CCRT.
Patients and Methods
Study design and population. This was a retrospective cohort study.
A total of 130 patients were diagnosed as having pharyngeal cancer
at the Okayama University Hospital Head and Neck Cancer Center
(Okayama, Japan) and received CCRT between April, 2013 and
March, 2017. Exclusion criteria were as follows: complete data not
acquired (59 patients); irradiated area did not include the oral cavity
(25 patients); or edentulous patients (two patients). As a result, data
from 44 patients were analyzed (Figure 1).
This study was approved by the Ethics Committee of the
Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences and the Okayama University Hospital (no.
1802-018). Informed consent was obtained from each participant.
General and oral conditions. The data for the general and oral
conditions were collected from medical and dental records. These
items were age, sex, body weight, smoking habit, drinking habit,
medical history, radiation dose, anticancer agent menu, cancer stage
(International Classification of Diseases for Oncology ICD-10
version 2015) (16), primary cancer site, center site of the irradiated
area, incipient or recurrent cancer, number of teeth present, possible
oral factors causing injury to the oral mucosa, nutrition by
gastrogavage/nasoenteric, xerostomia, and amount of anti-
inflammatory gargle agent used. Factors causing injury to the oral
mucosa, such as malalignment and remaining tooth roots, were
diagnosed by a dentist prior to cancer therapy. Furthermore, serum
markers, including white blood cell (WBC) count, serum albumin,
serum creatinine, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and C-reactive protein (CRP), were also
evaluated. The serum WBC count was determined by the electrical
resistance method using an automatic analyzer (BAYER
ADVIA2120; Bayer Ltd., Osaka, Japan). The serum Alb level was
measured by the modified bromocresol purple method using an
automatic analyzer (JEOL BM 8040 and BM 2250; Jeol Ltd., Tokyo,
Japan). The serum creatinine level was measured by enzymatic
methods using an automatic analyzer (JEOL BM 8040 and JCA-BM
6050; Jeol Ltd.). The serum CRP concentration was measured using
the latex agglutination method using an automatic analyzer (JEOL
BM 8040 and BM 2250; Jeol Ltd.).
The serum creatinine level (SCr) was converted to creatinine
clearance (Ccr) in males by the Cockcroft-Gault equation (17,18),
as follows: 
Ccr (mI/min)=[140 – age (years)] × weight (kg) ÷ [72× (SCr + 0.2)].
For females, Ccr values thus calculated were multiplied by 0.85.
Based on previous studies (19-23), a Ccr cut-off of 60 ml/min was
used. Ccr of 60 mI/min or less was defined as moderate/severe RD,
and Ccr of 60 mI/min or more was defined as normal/mild RD.
The scale for OM was according to the Common Terminology
Criteria for Adverse Events ver. 3.0 (2006) (24) as follows: 0, None;
1, erythema of the mucosa; 2, patchy ulcerations or pseudomembranes;
3, confluent ulcerations or pseudomembranes, bleeding with minor
trauma; 4, tissue necrosis, significant spontaneous bleeding, life-
threatening consequences; and 5, death. Treatment plans were
determined by standard protocols according to the tumor stage and
physical condition of the patient. 
Statistical analysis. The patients were divided into two groups
according to OM: grade 0-2 (N=20) and grade 3 (N=24); there were
no patients with grade 4 or 5 during the study period. The Mann–
Whitney U-test and chi-squared test were used to assess significant
differences in clinical variables between the two groups. The
cumulative incidence of overall OM was estimated using the Kaplan–
Meier method, and differences were tested using the log-rank test.
The follow-up period lasted until a CCRT dose of 60 Gy was reached.
Backward stepwise regression procedures for the Cox proportional
hazards model were used to determine significant prognostic factors.
The variable reduction method (likelihood ratio) was adopted for the
Cox proportional hazards model, and the remaining factors were re-
evaluated using the forced-input method. In the Cox proportional
hazards model, the following candidate variables were adjusted for
covariates: Smoking habit, drinking habit, incipient cancer, cancer
stage, toxicity of anticancer drug agents, number of teeth present,
factor causing injury to the oral mucosa, WBC count, serum albumin
concentration, center of the irradiated area, and renal dysfunction.
Anticancer agents were divided into two categories according to
toxicity, either liver or kidney. Values of p<0.05 were considered
significant. All analyses were performed using SPSS 15.0 J for
Windows (IBM Japan, Tokyo, Japan).
Results
Table I shows the comparisons of baseline variables and
events in CCRT between the two OM groups, grade 0-2 and
grade 3. There were no significant differences in the
variables between the two groups, except for Ccr, which was
significantly lower in the latter group.
Table II shows the distribution of OM during the CCRT
period in the normal/mild RD and the moderate/severe RD
groups. There were no significant differences in the
distribution of severity between the two groups. 
The Cox proportional hazards regression model
demonstrated that the nasopharynx/oropharynx as the site of
the irradiated area and RD were significantly associated with
the incidence of severe OM (grade 3) (Table III). Figure 2
shows the association between RD and the overall incidence
of severe OM for non-adjusted and adjusted cases. Figure 3
shows the association between the site of the irradiated area
(hypopharynx vs. nasopharynx/oropharynx) and the overall
incidence of severe OM for non-adjusted and adjusted cases.
Discussion
As well as type of CCRT, a variety of factors including age,
nutritional status, type of malignancy, pretreatment oral
condition, oral care during treatment, and pretreatment
neutrophil counts can be associated with the development of
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OM in patients with HNC (25, 26). However, the details of
the mechanism of OM development are completely
unknown, and its control during CCRT remains challenging.
To the best of our knowledge, this is the first longitudinal
study to investigate the association between OM and RD
during CCRT. The present study showed that the relative
high-risk factors for severe OM (grade 3) were the
nasopharynx/oropharynx as site of irradiation and RD (Table
III). This may provide a new insight into OM and predict
developing OM during CCRT by focusing on RD.
It was found that RD was a possible risk factor for severe
OM (Table III). Since impaired renal function is associated
with decreased renal clearance of drugs, it can lead to high
incidences and severities of adverse events in patients taking
anticancer agents (22). In CCRT, anticancer agents or
molecular target drugs, including cisplatin, carboplatin,
methotrexate, tegafur, and cetuximab, are widely used. One
of the major side-effects of these anticancer agents is RD
(14). Therefore, prescription of anticancer agents should be
carefully considered in order to prevent severe OM in
patients with HNC during CCRT in accordance with the
estimated Ccr.
When the center of the irradiated area was the
nasopharynx/oropharynx, the risk of severe OM was
significantly higher than when it was the hypopharynx (Table
III, Figure 3). The radiation dose is gradually attenuated
from the center of the target lesion to the neighboring area
(27). Since the center of the irradiated area was closer to the
oral cavity when the site was the nasopharynx/oropharynx
rather than the hypopharynx, it may be reasonable that
severe OM developed in cases with the center site being the
nasopharynx/oropharynx.
Because of intense pain, patients with grade 3-4 mucositis
require feeding tubes, total parenteral nutrition, and opioid
analgesics (12, 28). Therefore, clinicians should pay attention
to nutritional support, oral decontamination, palliation of dry
mouth, management of oral bleeding, and therapeutic
interventions during the management of OM in patients treated
with CCRT (29). In the present study, all patients received
continuous oral hygiene care by nurses, dentists, or dental
hygienists. When patients have RD and the center site of the
irradiated area is the nasopharynx/oropharynx, clinicians
should understand the high risk of severe OM before CCRT.
Furthermore, more appropriate management of OM is needed
in the future. 
CCRT is one of the most commonly used cancer
treatments, in which severe OM develops at a high rate.
CCRT can more easily induce severe OM than radiotherapy
alone. Furthermore, the risk of severe OM in radiotherapy
without covering the oral cavity, such as intensity-modulated
radiation therapy, may be similar to that of chemotherapy
alone (27). Since the goal was to investigate more critically
the risk of OM in CCRT, CCRT cases in which the irradiated
area did not cover the oral cavity were excluded. 
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Figure 1. Flowchart of the study. CCRT: Concurrent chemoradiotherapy.
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Table I. Relationships between grade of oral mucositis and other factors.
                                                                                                                       Severity of oral mucositis
Baseline parameter                                                                Grade 0-2 (N=20)                                 Grade 3 (N=24)                                     p-Value*
Age (years)
   Median (IQR)                                                                      64.0 (56.8-68.5)                                  70.5 (62.0-76.0)                                       0.050
Gender: n (%)
   Male                                                                                           16 (80.0)                                              20 (83.3)                                             0.775
Body weight (kg)
   Median (IQR)                                                                      55.3 (49.1-60.4)                                  56.0 (49.6-60.7)                                       0.991
Habit: n (%)
   Smoking                                                                                    16 (80.0)                                              20 (83.3)                                             0.261
   Drinking                                                                                    15 (75.0)                                              22 (91.7)                                             0.495
Systemic diseases
   No                                                                                               2 (10.0)                                                 2 (8.3)                                               0.919
   Hypertension                                                                              5 (25.0)                                                5 (20.8)                                                
   Diabetes                                                                                       1 (5.0)                                                 3 (12.5)                                                
   Liver diseases                                                                             3 (15.0)                                                 2 (8.3)                                                 
   Cancer except for neck cancer                                                  3 (15.0)                                                3 (12.5)                                                
   Others                                                                                          6 (30.0)                                                9 (37.5)                                                
Radiation dose (Gy)
   Median (IQR)                                                                      60.0 (60.0-61.0)                                  60.0 (60.0-60.0)                                       0.834
Anticancer agent: n (%)
   Tegafur                                                                                        6 (30.0)                                                3 (12.5)                                              0.392
   Tegafur + nedaplatin                                                                  3 (15.0)                                                6 (25.0)                                                
   Tegafur + cisplatin                                                                     9 (45.0)                                               10 (41.7)                                               
   Cetuximab                                                                                   2 (10.0)                                                5 (20.8)                                                
Cancer stage: n (%)
   0                                                                                                   0 (0.0)                                                  1 (4.2)                                               0.208
   I                                                                                                    0 (0.0)                                                  1 (4.2)                                                 
   II                                                                                                  2 (10.0)                                                 0 (0.0)                                                 
   III                                                                                                7 (35.0)                                                6 (25.0)                                                
   IVA                                                                                             10 (50.0)                                              15 (62.5)                                               
   IVB                                                                                              0 (0.0)                                                  0 (0.0)                                                 
   IVC                                                                                              1 (5.0)                                                  1 (4.2)                                                 
Primary cancer site: n (%)
   Nasopharynx                                                                                1 (5.0)                                                 6 (25.0)                                              0.220
   Oropharynx                                                                                 6 (30.0)                                                6 (25.0)                                                
   Hypopharynx                                                                             13 (65.0)                                              11 (45.8)                                               
   Multifocal                                                                                    0 (0.0)                                                  1 (4.2)                                                 
Center of irradiated area
   Nasopharynx or oropharynx                                                      7 (35.0)                                               13 (54.2)                                             0.204
   Hypopharynx                                                                             13 (65.0)                                              11 (45.8)                                               
Incipient or recurrent cancer
   Incipient                                                                                     19 (95.0)                                             24 (100.0)                                            0.268
WBC count (n/µl)
   Median (IQR)                                                                5410.0 (4757.5-6467.5)                      5345.0 (4390.0-6145.0)                                 0.604
Alb (g/dl)
   Median (IQR)                                                                         4.0 (3.8-4.3)                                        4.0 (3.7-4.3)                                          0.924
Ccr (ml/min)
   Median (IQR)                                                                      62.2 (56.1-73.7)                                  55.2 (45.6-61.2)                                       0.007
AST (U/l)
   Median (IQR)                                                                      20.0 (16.8-32.0)                                  20.0 (16.8-25.5)                                       0.595
ALT (U/l)
   Median (IQR)                                                                      17.5 (11.8-24.3)                                  16.5 (13.0-29.0)                                       0.759
CRP (mg/dl)
   Median (IQR)                                                                         0.2 (0.1-0.3)                                        0.1 (0.1-0.3)                                          0.464
Number of teeth present
   Median (IQR)                                                                      16.5 (10.0-26.0)                                  21.5 (15.5-26.0)                                       0.345
Factor causing injury to the oral mucosa
   N (%)                                                                                          4 (20.0)                                                4 (16.7)                                              0.775
Event during CCRT: n (%)
   Nutrition by gastrogavage                                                        15 (75.0)                                              21 (87.5)                                             0.284
   Nutrition by nasoenteric feeding                                               2 (10.0)                                                3 (12.5)                                              0.795
   Xerostomia                                                                                14 (70.0)                                              20 (83.3)                                             0.293
   Amount of gargle agent (l)                                                    3.0 (2.0-5.8)                                        3.8 (2.6-6.1)                                          0.635
IQR: Interquartile range; WBC: white blood cell count; Alb: albumin; Ccr: creatinine clearance (converted by Cockcroft-Gault); AST: aspartate
aminotransferase; ALT: alanine aminotransferase; CRP: C-reactive protein. CCRT: Concurrent chemoradiotherapy; *Mann–Whitney U-test or chi-
squared test.
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Figure 2. Association between renal dysfunction and overall incidence of oral mucositis (grade 3) for non-adjusted (A) and adjusted (B) cases (adjusted
for covariates shown in Table III). Moderate/severe renal function: Creatinine clearance (Ccr) <60 mI/min; normal/mild renal dysfunction: Ccr≥60 mI/min.
Figure 3. Association between the center site of the irradiated area (hypopharynx vs. nasopharynx/oropharynx) and the overall incidence of oral
mucositis (grade 3) for non-adjusted (A) and adjusted (B) cases (adjusted for covariates shown in Table III).
Table II. Relationship between renal dysfunction (RD) and oral mucositis (OM).
                                                                                                                                          RD, n (%)
OM                                          Total, n (%)                               Normal/mild (N=20)                          Moderate/severe (N=24)                          p-Value
None                                           2 (4.5)                                              1 (5.0)                                                      1 (4.2)                                           0.300
Grade 1                                      6 (13.6)                                            3 (15.0)                                                   3 (12.5)                                             
Grade 2                                    12 (27.3)                                            8 (40.0)                                                   4 (16.7)                                             
Grade 3                                    24 (54.5)                                            8 (40.0)                                                 16 (66.7)                                             
Grade 4                                      0 (0.0)                                              0 (0.0)                                                      0 (0.0)                                               
Grade 5                                      0 (0.0)                                              0 (0.0)                                                      0 (0.0)                                               
CCRT: Concurrent chemoradiotherapy; RD: renal dysfunction. patients were divided into those with normal/mild RD (creatinine clearance: Ccr ≥60 ml/min)
and moderate/severe RD (Ccr <60 ml/min) groups. *Chi-squared test.
A previous study reported that the overall incidence of
OM in CCRT was 80% (30). For severe OM (>grade 2),
the incidence was about 45% in patients receiving CCRT
(10, 25, 26). In the present study, the overall OM incidence
was 95.5%, and severe OM was observed in 54.5% of
patients (Table II). On the other hand, in patients receiving
a typical course of RT (6-7 weeks), OM appears as
erythema of the oral mucosa in the first 2-3 weeks of RT.
In the present study, OM appeared 2-3 weeks after the start
of CCRT (data not shown). Thus, the prevalence and
timing of developing OM in this study were similar to
other studies. 
The present study had certain limitations. Firstly, all
patients were recruited from the Okayama University
Hospital. This may limit the application of our findings to
the general population. Secondly, the number of patients
was small. Further studies with a larger number of patients
are required. Thirdly, this was a retrospective cohort study.
Prospective cohort or intervention studies may confirm this
relationship. Finally, aIthough there was adjustment for
potential confounders, there may be further confounders
including oral microflora or genetic factors, and the
detailed mechanism relating RD and OM remains
unknown.
In conclusion, this retrospective study showed that RD at
baseline and nasopharynx/oropharynx as the center of the
irradiated area were associated with a high risk of severe OM
in patients with pharyngeal cancer those with CCRT
including irradiation to the oral cavity.
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